Welcome! Thank you for subscribing to the Earnings360 newsletter, your daily source for quarterly earnings news and updates.
Each morning edition contains a wrap-up of today's pre-market earnings announcements and yesterday's earnings announcements after the closing bell.
Please take a moment to confirm your subscription below so we can ensure these updates reach your inbox.
Confirm Your Subscription Here
The Earnings360 Team
Further Reading from MarketBeat Media Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change EverythingWritten by Jeffrey Neal Johnson. Published 11/18/2025. 
Key Points - Merck's major acquisition of Cidara Therapeutics demonstrates a clear and proactive strategy to build its next-generation long-term revenue drivers.
- The acquisition secures a high-potential, late-stage antiviral drug that has already earned key designations from the FDA for its innovative approach.
- This strategic move reinforces Merck’s strong financial fundamentals and its unwavering commitment to creating sustainable, long-term value for its shareholders.
In one of the most decisive strategic moves in the biotech sector this year, pharmaceutical titan Merck & Co. (NYSE: MRK) has committed a formidable $9.2 billion in cash to acquire Cidara Therapeutics (NASDAQ: CDTX). The announcement immediately sent Cidara’s stock price soaring more than 100%—a clear win for its investors. Some of Wall Street's biggest players have been taking advantage of the same early-morning price behavior for years — a pattern that appears shortly after the opening bell when overnight institutional flows hit the market. Most retail traders never notice it, but Dave Aquino has spent years studying this window and developed a simple routine built to capitalize on it without relying on news or predictions.
He calls it the Good Morning Cash Plan — a single morning setup designed to give traders a structured, rules-based approach before the day even begins. Dave breaks down the full method in a free training session, including how he identifies the setup each morning. Watch the Good Morning Cash Plan training here For Merck, the market's muted reaction reflects confidence in a carefully planned strategic move. The acquisition is more than a headline; it underscores Merck's forward-looking plan to assemble the next generation of revenue drivers from a position of financial and operational strength. A Strategic Imperative: Securing the Next Decade For any pharmaceutical leader, managing the lifecycle of blockbuster drugs is the ultimate strategic test. Merck is proactively addressing the expected 2028 patent expiration of its cancer therapy Keytruda, a medicine that has reshaped oncology and currently contributes a sizeable portion of the company's revenue. Rather than waiting for that challenge, Merck is executing a clear, science-led business development strategy to broaden and diversify its portfolio for the next decade. In short, this is a deliberate strategic offensive rather than a reactive measure. The Cidara acquisition exemplifies that approach and is enabled by Merck’s strong financial position. With trailing twelve-month net income north of $17 billion and a healthy debt-to-equity ratio (D/E) of 0.69, Merck can absorb a $9.2 billion deal without unduly straining operations or shareholder commitments. It follows last month's completed acquisition of Verona Pharma and its promising COPD drug, OHTUVAYRE. These moves show management's discipline in using Merck’s balance sheet to buy external innovation and reduce future risk. By expanding into the respiratory antiviral space, Merck gains exposure to recurring revenues in the large global influenza market—a strategic diversification away from the intensely competitive oncology landscape. CD388: What Makes a Flu Drug Worth Billions? At the heart of the multi-billion-dollar valuation is Cidara's crown jewel: an investigational drug known as CD388. CD388 isn't merely an incremental flu treatment; it could represent a meaningful shift in influenza prevention, which helps explain the premium price tag. Its value rests on several attributes that lower development risk and boost commercial potential. - Advanced and De-Risked: CD388 is already in Phase 3 clinical trials, the final and most costly stage before regulatory submission. That advanced position means much of the early scientific and clinical risk has been cleared—an important factor for an acquirer like Merck.
- A Potential New Standard of Care: As a long-acting antiviral, CD388 is designed to deliver season-long protection against both influenza A and B from a single dose. That one-and-done approach could be a meaningful advantage over annual vaccines, which must be reformulated each year and can vary in effectiveness depending on circulating strains. CD388's strain-agnostic design aims to be effective regardless of which variants predominate in a given season.
- Regulatory Confidence: The drug has received both Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration (FDA). Those designations are reserved for therapies that address serious conditions and may represent a substantial improvement over existing options, potentially speeding the path to market.
Merck's management has signaled high expectations, projecting a commercial opportunity that could exceed $5 billion annually. That blockbuster potential helps justify the acquisition price and its possible impact on Merck's top line. What This Deal Means for Investors For investors, Merck's purchase of Cidara strengthens the long-term bullish case for the stock. The deal creates a concrete growth pathway that helps insulate the company from future patent cliffs, a key risk for pharmaceutical valuations. It shows management is thinking long term and is willing to deploy capital decisively to mitigate those risks. That strategic foresight is supported by attractive financial fundamentals. Merck's stock trades at a forward price-to-earnings ratio (P/E) of roughly 10.4, a valuation that appears reasonable given its growth prospects and relative to the broader market. The company's commitment to shareholder returns remains clear, with a dividend yield of 3.48% that has been raised for 14 consecutive years. That payout is supported by a payout ratio of about 42.8% of earnings, leaving ample capital for reinvestment and strategic deals like this one. With a consensus analyst price target of around $104.50, the stock implies roughly 12% near-term upside. The shares have already gained more than 10% in the past month, and this acquisition provides a fundamental catalyst to sustain positive momentum. The Cidara deal is more than a pipeline add-on; it signals proactive leadership and long-term value creation, reaffirming Merck's standing as a blue-chip innovator preparing for the next phase of growth.
| 
